New drug cocktail aims to shrink High-Risk throat tumors
NCT ID NCT07524413
First seen Apr 14, 2026 · Last updated May 17, 2026 · Updated 4 times
Summary
This study tests whether adding a targeted drug (Becotatug Vedotin) to standard immunotherapy and chemo-radiation can better shrink or control high-risk nasopharyngeal cancer. About 514 adults with advanced throat cancer will be randomly assigned to receive either the new combo or the usual treatment. The goal is to see if the new approach leads to more complete tumor disappearance and longer cancer-free survival.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NASOPHARYNGEAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.